|
Inhibitor | Clinical trial | Reference |
|
Trabedersen (AP12009) | phase I/II clinical trial; advanced pancreatic or colorectal cancer and malignant melanoma | [41] |
|
Trabedersen | phase I/II study; high-grade glioma | [42] |
|
Fresolimumab (GC1008) in combination with radiation therapy | phase I trial; metastatic breast cancer patients | NCT01401062 |
|
Fresolimumab | phase I trial; malignant melanoma or renal cell carcinoma | [43] |
NCT00356460 |
|
Galunisertib (LY2157299) in combination with gemcitabine | phase 1b/2 study; patients with solid malignancy | [44] |
NCT01373164 |
|
Galunisertib in combination with nivolumab | phase I/II study; advanced refractory solid tumors and in recurrent or refractory non-small cell lung cancer or hepatocellular carcinoma | NCT02423343 |
|
PF-03446962 | phase I/II study; advanced hepatocellular carcinoma | [45] |
NCT00557856 |
|
Tasisulam | open-label phase III trial; melanoma | [46] |
NCT01006252 |
|
Galunisertib in combination with durvalumab | phase I study; pancreatic cancer patients | NCT02734160 |
|